{"url_path":"/sec/tak/10-k/2026/item-4a","section_key":"item-4a","section_title":"Item 4A Unresolved Staff Comments","topic":"sec","document":{"doc_type":"20-F","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1395064/0001395064-26-000177-index.html","accession_number":"0001395064-26-000177","cik":"0001395064","ticker":"TAK","issuer_name":"TAKEDA PHARMACEUTICAL CO LTD","edgar_url":"https://www.sec.gov/Archives/edgar/data/1395064/0001395064-26-000177-index.html","primary_entity_key":"0001395064","primary_entity_name":"TAKEDA PHARMACEUTICAL CO LTD"},"word_count":11,"has_tables":true,"body_markdown":"Item 4A. Unresolved Staff Comments\n\nNot applicable.\n\n58\n\n[Table of Contents](#i89761be648564855b53fa24df8e6ee90_10)"}